Ascendis Pharma (ASND) Tops Q1 EPS by 31c

Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of (EUR0.06), EUR0.31 better than the analyst estimate of (EUR0.37). Revenue for the quarter came in at EUR2.1 million versus the consensus estimate of EUR2.24 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Chewy (CHWY) Reports In-Line Q2 EPS, Offers Guidance
• Boston Properties Inc. (BXP) PT Raised to $68 at Truist Securities
• ABM Industries (ABM) Reports In-Line Q3 EPS; raises guidance